Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B608031-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $615.90 | |
B608031-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,844.90 |
Synonyms | HY-137561 | 2376257-44-0 | (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid | BDBM50594476 | CS-0140405 | GLXC-26826 | Bexotegrast | PLN74809 | PLN-74809 | Butanoic acid, 4-[(2-methox |
---|---|
Specifications & Purity | Moligand™ |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of integrin; alpha V subunit |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid |
---|---|
INCHI | InChI=1S/C27H36N6O3/c1-36-18-17-33(15-5-4-8-21-12-11-20-7-6-14-28-25(20)31-21)16-13-24(27(34)35)32-26-22-9-2-3-10-23(22)29-19-30-26/h2-3,9-12,19,24H,4-8,13-18H2,1H3,(H,28,31)(H,34,35)(H,29,30,32)/t24-/m0/s1 |
InChi Key | CWOFQJBATWQSHL-DEOSSOPVSA-N |
Canonical SMILES | COCCN(CCCCc1nc2c(CCCN2)cc1)CC[C@@H](C(=O)O)Nc1ncnc2ccccc12 |
Isomeric SMILES | COCCN(CCCCC1=NC2=C(CCCN2)C=C1)CC[C@@H](C(=O)O)NC3=NC=NC4=CC=CC=C43 |
PubChem CID | 135390719 |
PubChem CID | 135390719 |
---|---|
BindingDB Ligand | 465216 |
CAS Registry No. | 2376257-44-0 |
Enter Lot Number to search for COA:
1. Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke P, IT-LIVER Consortium. (2016) TGF-β signalling and liver disease.. FEBS J, 283 (12): (2219-32). [PMID:26807763] [10.1021/op500134e] |
2. Saito A, Horie M, Nagase T. (2018) TGF-β Signaling in Lung Health and Disease.. Int J Mol Sci, 19 (8): (2460). [PMID:30127261] [10.1021/op500134e] |
3. Decaris ML, Schaub JR, Chen C, Cha J, Lee GG, Rexhepaj M, Ho SS, Rao V, Marlow MM, Kotak P et al.. (2021) Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF.. Respir Res, 22 (1): (265). [PMID:34666752] [10.1021/op500134e] |